Trial abstract · §3
GNRH-PULSATILE-HH — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Induction of ovulation or spermatogenesis by pulsatile administration in hypogonadotrophic hypogonadism | Effective when delivered by pump at a physiological pulse frequency. Non-pulsatile administration downregulates the receptor, which is the pharmacological reason the Institute grades unregulated intermittent use very low certainty | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Gonadorelin from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Headache | — | — | Reported |
| Nausea | — | — | Reported |
| Abdominal discomfort | — | — | Reported |
| Flushing | — | — | Reported |
| Injection-site reaction | — | — | Reported |
| Ovarian hyperstimulation | — | — | With pulsatile ovulation-induction use |
| Paradoxical axis suppression | — | — | The predictable consequence of continuous or frequent non-pulsatile administration, and the principal risk of uncontrolled use |
Compound Evidence Institute · CEI-TR-0145/3 · https://compoundevidence.com/trials/gnrh-pulsatile-hh/results/ · retrieved 30 July 2026